A safety warning has been issued by Australia’s national medicines regulator over a so-called “Hollywood drug” used to treat type 2 diabetes and obesity.
The Therapeutic Goods Association has updated its product data for the relatively new class of medicines known as GLP-1 receptor agonists, warning of an increased risk of potential suicidal ideation.
In a statement to 1News, New Zealand’s Ministry of Health said it was aware of the Australian advancement and was seeking further information from companies marketing GLP-1 inhibitors hear.The class includes semaglutide, the drug marketed in Australia as Ozempic.
The drug is taken as a weekly injection to treat diabetes, but is also widely used for weight loss, making it popular among celebrities.
other GLP-1 receptor agonists included in the warning were semaglutide sold as Wegovy; liraglutide sold as saxenda; dulaglutide (Trulicity) and tirzepatide (Mounjaro).
The TGA said patients taking any of these medicines should tell thier health professional if they experienced new or worsening depression, suicidal thoughts or any unusual changes in mood or behavior.
The updates have been issued after investigations by the TGA and other international regulators.The product warning for tirzepatide (Mounjaro) was also updated to reflect a risk of decreased effectiveness of oral contraception when first taking or increasing the dose of the drug.
Worth a look